The ADJUVANT, EVAN, and ADAURA trails have similarly confirmed that adjuvant EGFR-TKI therapies could provide greater benefits for EGFR-positive NSCLC patients in terms of DFS compared to adjuvant chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.